Is Sarepta a buy?
By Gabriel Cooper
Is Sarepta a buy?
Sarepta Therapeutics Inc (SRPT) stock is down -32.42% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives SRPT stock a score of 41 out of a possible 100. This means analysts expect the stock to climb 32.40% over the next 12 months.
Will Sarepta stock go up?
Stock Price Forecast The 19 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 125.00, with a high estimate of 192.00 and a low estimate of 86.00. The median estimate represents a +46.01% increase from the last price of 85.61.
Why is Sarepta stock down today?
Sarepta Stock Sinks After Announcing a Stock Sale. Sarepta Therapeutics stock is falling after the biotech company said it would sell more stock and provided an update on product revenue. Sarepta said that it would post third-quarter sales of $166.9 million.
Who makes Sarepta?
As of the end of 2019, the company has two approved drugs (see the Products section below)….Sarepta Therapeutics.
| Traded as | Nasdaq: SRPT Russell 1000 Index component |
|---|---|
| Headquarters | Cambridge |
| Key people | Douglas S. Ingram (CEO & President) |
| Revenue | $301 Million(2018) |
| Website |
Why is Srpt stock falling?
It’s the Latest ‘Bad’ News. Sarepta Therapeutics stock is falling after the biotech company said it would sell more stock and provided an update on product revenue. Sarepta said that it would post third-quarter sales of $166.9 million. Sarepta stock had 6.6% in premarket trading after gaining 4.1% on Tuesday.
What does Sarepta Therapeutics do?
Sarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. We are in a daily race to save lives stolen or impacted by rare disease.
Is Sarepta a biotech company?
Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases.
Is Sarepta a good place to work?
Management does everything possible for Sarepta to be very nice and pleasant place to work. Recruitment process is rather strict and meticuluos, therefore employees are highly knowledgible, intelligent, professional, patients dedicated, and nice decent people to work with.
Is Sarepta a good company?
Employees are valued Everything about Sarepta is amazing. Great culture, great mission, and employees are set up for success. Sarepta puts a huge focus on career growth and personal growth. Competitive compensation package.
Is Sarepta a public company?
Sarepta’s common stock is traded on the NASDAQ Global Select Market under the ticker symbol “SRPT”. Sarepta completed its initial public offering on June 4, 1997 under the name AntiVirals Inc., which was changed to AVI BioPharma, Inc. in 1997. The company was subsequently renamed Sarepta Therapeutics, Inc.
When did Sarepta go public?
June 4, 1997
Sarepta completed its initial public offering on June 4, 1997 under the name AntiVirals Inc., which was changed to AVI BioPharma, Inc.
How many employees does Sarepta have?
As of the end of 2018, Sarepta had 499 employees, including 255 working in R&D and 48 in sales. The company’s total headcount is now tracking to about 900 by the end of 2019, Ingram told investors during the firm’s second-quarter earnings call in August.
Is Sarepta a biopharmaceutical company?
Sarepta Therapeutics Inc. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
What does Sarepta do for a living?
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Did the CEO of Sarepta buy $2 million of stock?
Sarepta Stock Bears Are Celebrating, but the CEO Scooped Up Shares. The biopharmaceutical firm’s shares are on the ropes, but CEO Douglas Ingram bought $2 million of Sarepta stock, and director Richard Barry bought $1.1 million of stock.
What does estestimated return mean for Sarepta Therapeutics?
Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
